Your browser doesn't support javascript.
loading
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall, David; Hernández-Prat, Anna; García-Alonso, Sara; Arpí-Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia, Cristina; Morancho, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi, Mohammad A; Eroles, Pilar; Cejalvo, Juan Miguel; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell, Joan.
Affiliation
  • Casadevall D; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Hernández-Prat A; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • García-Alonso S; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Arpí-Llucià O; Experimental Oncology Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Menéndez S; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Qin M; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Guardia C; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Morancho B; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Sánchez-Martín FJ; Preclinical & Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO)-CIBERONC, Barcelona, Spain.
  • Zazo S; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Gavilán E; Pathology Department, IIS-Hospital Universitario Fundación Jiménez Díaz-CIBERONC, Madrid, Spain.
  • Sabbaghi MA; Department of Experimental Oncology, Instituto Europeo di Oncologia (IEO). Milan, Italy.
  • Eroles P; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
  • Cejalvo JM; INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Universitat de València-CIBERONC, Valencia, Spain.
  • Lluch A; INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Universitat de València-CIBERONC, Valencia, Spain.
  • Rojo F; INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Universitat de València-CIBERONC, Valencia, Spain.
  • Pandiella A; Pathology Department, IIS-Hospital Universitario Fundación Jiménez Díaz-CIBERONC, Madrid, Spain.
  • Rovira A; Centro de Investigación del Cáncer, CSIC-IBSAL and CIBERONC, Salamanca, Spain.
  • Albanell J; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
Mol Cancer Res ; 20(7): 1108-1121, 2022 07 06.
Article in En | MEDLINE | ID: mdl-35348729
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Immunoconjugates Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Res Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Immunoconjugates Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Res Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2022 Document type: Article Affiliation country: